The Nomination Committee Proposes Changes to the Board of Spago Nanomedical for Increased Commercial Focus
Spago Nanomedical Hans Arwidsson is proposed as new chairman of the board and Alan Raffensperger is proposed as new board member.
Uncategorized
Biovica establishes DiviTum(R) TKa Commercialization Partnership in Italy
Biovica International Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum® TKa assay in Italy.
Biovica establishes DiviTum(R) TKa Commercialization Partnership in Italy Read More »
Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration
Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.
Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration Read More »
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA announced it has called an extraordinary general meeting of shareholders to be held at 10:00 a.m. CEST on Friday, April 28, 2023 in Geneva.
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders Read More »
PHC Corporation and NovaScan, Inc. Launch Collaboration to Explore the Feasibility of a Device that Supports Non-melanoma Skin Cancer Detection
PHC Corporation and NovaScan, Inc. announce the launch of a collaboration through which they will seek to explore the feasibility of MarginScanTM, an investigational “ex vivo” medical device that will seek to support physicians in detecting non-melanoma skin cancers.
Skanska signs additional contract to expand hospital in Portland, Oregon, USA, for USD 111M, about SEK 1.2 billion
Skanska has signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.
Notice of Intention to Delist From The London Stock Exchange
OKYO Pharma Limited announces that it has applied to the UK Financial Conduct Authority and London Stock Exchange plc to effect a cancellation of its ordinary shares of no par value each from listing on the standard segment of the FCA’s Official List and trading on the main market for listed securities of the LSE
Notice of Intention to Delist From The London Stock Exchange Read More »
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer into their respective corporate health programs.
Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published
BioArctic AB announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta protofibril[1] antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using a disease simulation model in the peer-reviewed journal Neurology and Therapy.
iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.
iNtRON Biotechnology has announced that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.